^
    Back
    Association details:
    Biomarker:POT1 mutation
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Gazyva (obinutuzumab) (CD20 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

    Excerpt:
    In addition, POT1 mutations were associated with shorter OS in patients receiving Clb-R or Clb-G (hazard ratio [HR], 2.9; 95% CI, 1.2-7.1; P = .011)...the study identifies mutations in KRAS and POT1 as novel determinants of outcome after chemoimmunotherapy using chlorambucil and anti-CD20 treatment.
    Secondary therapy:
    chlorambucil
    DOI:
    10.1182/blood-2016-01-691550